SG10201601913RA - Yeast-brachyury immunotherapeutic compositions - Google Patents

Yeast-brachyury immunotherapeutic compositions

Info

Publication number
SG10201601913RA
SG10201601913RA SG10201601913RA SG10201601913RA SG10201601913RA SG 10201601913R A SG10201601913R A SG 10201601913RA SG 10201601913R A SG10201601913R A SG 10201601913RA SG 10201601913R A SG10201601913R A SG 10201601913RA SG 10201601913R A SG10201601913R A SG 10201601913RA
Authority
SG
Singapore
Prior art keywords
yeast
immunotherapeutic compositions
brachyury immunotherapeutic
brachyury
compositions
Prior art date
Application number
SG10201601913RA
Inventor
Claudia Palena
Zhimin Guo
David Apelian
Jeffrey Schlom
Original Assignee
Globeimmune Inc
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Globeimmune Inc, Us Health filed Critical Globeimmune Inc
Publication of SG10201601913RA publication Critical patent/SG10201601913RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/062—Ascomycota
    • A61K36/064—Saccharomycetales, e.g. baker's yeast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6006—Cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
SG10201601913RA 2011-03-17 2012-03-19 Yeast-brachyury immunotherapeutic compositions SG10201601913RA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161453656P 2011-03-17 2011-03-17

Publications (1)

Publication Number Publication Date
SG10201601913RA true SG10201601913RA (en) 2016-05-30

Family

ID=46831122

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201601913RA SG10201601913RA (en) 2011-03-17 2012-03-19 Yeast-brachyury immunotherapeutic compositions
SG2013068176A SG193396A1 (en) 2011-03-17 2012-03-19 Yeast-brachyury immunotherapeutic compositions

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG2013068176A SG193396A1 (en) 2011-03-17 2012-03-19 Yeast-brachyury immunotherapeutic compositions

Country Status (19)

Country Link
US (5) US9198941B2 (en)
EP (2) EP3238731B1 (en)
JP (4) JP6068368B2 (en)
KR (1) KR102046449B1 (en)
CN (1) CN103648513B (en)
AU (3) AU2012228937B2 (en)
BR (1) BR112013023456B1 (en)
CA (1) CA2835475C (en)
DK (1) DK2685995T3 (en)
ES (1) ES2627979T3 (en)
HK (1) HK1245649A1 (en)
HU (1) HUE033491T2 (en)
IL (1) IL228421B (en)
MX (1) MX350661B (en)
PL (1) PL2685995T3 (en)
PT (1) PT2685995T (en)
RU (2) RU2619850C2 (en)
SG (2) SG10201601913RA (en)
WO (1) WO2012125998A1 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3061462B1 (en) 2007-07-02 2019-02-27 Etubics Corporation Methods and compositions for producing an adenovirus vector for use with multiple vaccinations
US9254320B2 (en) 2010-12-17 2016-02-09 Globeimmune, Inc. Compositions and methods for the treatment or prevention of human adenovirus-36 infection
MA34956B1 (en) 2011-02-12 2014-03-01 Globeimmune Inc THERAPY WITH YEAST FOR CHRONIC INFECTION WITH HEPATITIS B
CN103648513B (en) 2011-03-17 2018-10-12 全球免疫股份有限公司 Yeast-Brachyury (Brachyury) immunotherapeutic composition
BR112013032381B1 (en) 2011-06-14 2021-01-12 Globeimmune, Inc. yeast-based compositions and methods for treating or preventing infection by the hepatitis delta virus
CA2844500C (en) 2011-08-17 2022-05-10 Globeimmune, Inc. Yeast-muc1 immunotherapeutic compositions and uses thereof
CN104685360B (en) 2012-06-26 2018-02-13 比奥德希克斯股份有限公司 The mass spectrometry method of the cancer patient treated for the therapy for selecting and going selection generation immune response
WO2014031178A1 (en) 2012-08-24 2014-02-27 Etubics Corporation Replication defective adenovirus vector in vaccination
US20150224181A1 (en) 2012-09-14 2015-08-13 The United States Of America As Represented By The Secretary Department Of Health And Human Se Brachyury protein, non-poxvirus non-yeast vectors encoding brachyury protein, and their use
SG11201507328RA (en) * 2013-03-19 2015-10-29 Globeimmune Inc Yeast-based immunotherapy for chordoma
TWI728239B (en) 2013-03-26 2021-05-21 美商環球免疫公司 Compositions and methods for the treatment or prevention of human immunodeficiency virus infection
US9725494B2 (en) * 2013-05-17 2017-08-08 United States Of America, As Represented By The Secretary, Department Of Health And Human Services Soluble CD27 (sCD27) and the use thereof
TWI654200B (en) 2013-08-30 2019-03-21 環球免疫公司 Composition and method for treating or preventing tuberculosis
WO2015157639A1 (en) 2014-04-11 2015-10-15 Globeimmune, Inc. Yeast-based immunotherapy and type i interferon sensitivity
CA2974237C (en) 2015-01-09 2021-07-20 Etubics Corporation Methods and compositions for combination immunotherapy
WO2016172249A1 (en) 2015-04-20 2016-10-27 Etubics Corporation Methods and compositions for combination immunotherapy
JP7048482B2 (en) 2015-08-03 2022-04-05 アメリカ合衆国 Brachyury deletion variants, non-yeast vectors encoding Brachyury deletion variants, and their use
KR20180054587A (en) * 2015-08-03 2018-05-24 글로브이뮨 Modified yeast-brachyury immunotherapeutic composition
MX2018011491A (en) 2016-03-24 2019-08-01 Nantcell Inc Sequence arrangements and sequences for neoepitope presentation.
EP3463450A4 (en) * 2016-06-03 2020-07-29 Etubics Corporation Compositions and methods for tumor vaccination using prostate cancer-associated antigens
WO2018094190A2 (en) 2016-11-18 2018-05-24 Sanford Burnham Prebys Medical Discovery Institute Gut microbiota and treatment of cancer
SG11201909882SA (en) 2017-04-24 2019-11-28 Nantcell Inc Targeted neoepitope vectors and methods therefor
KR20200033351A (en) * 2017-08-15 2020-03-27 난트셀, 인크. HANK Cetuximab Combination and Method (HANK CETUXIMAB COMBINATIONS AND METHODS)
CN112543640A (en) * 2018-05-15 2021-03-23 全球免疫公司 Recombinant yeast lysates for inducing cellular immune responses
US11857620B2 (en) 2020-03-11 2024-01-02 Immunitybio, Inc. Method of inducing immunity against SARS-CoV-2 using spike (s) and nucleocapsid (N)-ETSD immunogens delivered by a replication-defective adenovirus
US20210284716A1 (en) 2020-03-11 2021-09-16 Immunitybio, Inc. ACE2-Fc Trap

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1036329A (en) 1908-11-19 1912-08-20 Edison Inc Thomas A Phonograph-reproducer.
FR2486400B1 (en) 1980-07-09 1986-05-30 Univablot MEDICINAL PRODUCTS BASED ON YEAST OR THEIR INSOLUBLE EXTRACTS
NZ199722A (en) 1981-02-25 1985-12-13 Genentech Inc Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain
US4775622A (en) 1982-03-08 1988-10-04 Genentech, Inc. Expression, processing and secretion of heterologous protein by yeast
US5310654A (en) 1985-07-31 1994-05-10 The Board Of Trustees Of The Leland Stanford Junior University Method for determining virulence of Yersinia
US5234830A (en) 1988-02-03 1993-08-10 Suntory Limited DNA encoding a KEX2 endoprotease without a C-terminal hydrophobic region
IL95019A0 (en) 1989-08-09 1991-06-10 Mycogen Corp Process for encapsulation of biologicals
US5830463A (en) 1993-07-07 1998-11-03 University Technology Corporation Yeast-based delivery vehicles
US5413914A (en) 1993-07-07 1995-05-09 The Regents Of The University Of Colorado Yeast assay to identify inhibitors of dibasic amino acid processing endoproteases
US5858378A (en) 1996-05-02 1999-01-12 Galagen, Inc. Pharmaceutical composition comprising cryptosporidium parvum oocysts antigen and whole cell candida species antigen
US20020044948A1 (en) 2000-03-15 2002-04-18 Samir Khleif Methods and compositions for co-stimulation of immunological responses to peptide antigens
EP1272213B1 (en) 2000-04-06 2006-03-08 SEER Pharmaceuticals, LLC. Microbial delivery system
US7083787B2 (en) 2000-11-15 2006-08-01 Globeimmune, Inc. Yeast-dendritic cell vaccines and uses thereof
US7439042B2 (en) 2002-12-16 2008-10-21 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
KR101455222B1 (en) 2002-12-16 2014-10-31 글로브이뮨 Yeast-based vaccines as immunotherapy
US20100034840A1 (en) * 2005-07-11 2010-02-11 David Apelian Compositions and methods for eliciting an immune response to escape mutants of targeted therapies
US20070172503A1 (en) 2005-12-13 2007-07-26 Mycologics,Inc. Compositions and Methods to Elicit Immune Responses Against Pathogenic Organisms Using Yeast Based Vaccines
CA2638815A1 (en) * 2006-02-02 2007-08-16 Globeimmune, Inc. Yeast-based vaccine for inducing an immune response
BRPI0709340A2 (en) * 2006-03-27 2013-04-16 Globeimmune Inc mutations and compositions and methods of use thereof
SG10201405420QA (en) 2007-02-02 2014-10-30 Globeimmune Inc Methods for producing yeast-based vaccines
EP2444410A3 (en) * 2007-02-28 2012-08-08 The Govt. Of U.S.A. As Represented By The Secretary Of The Department Of Health And Human Services Brachyury polypeptides and methods for use
CA2681246A1 (en) 2007-03-19 2008-09-25 Globeimmune, Inc. Compositions and methods for targeted ablation of mutational escape of targeted therapies for cancer
WO2009042642A2 (en) 2007-09-24 2009-04-02 President And Fellows Of Harvard College Compositions and methods for the treatment and prevention of ulcerative colitis and colon cancer
WO2010033841A1 (en) 2008-09-19 2010-03-25 Globeimmune, Inc. Immunotherapy for chronic hepatitis c virus infection
WO2010065626A1 (en) 2008-12-02 2010-06-10 Globeimmune, Inc. Genotyping tools, methods and kits
EP3320915A1 (en) * 2009-04-17 2018-05-16 Globeimmune, Inc. Combination immunotherapy compositions against cancer and methods
WO2011032119A1 (en) 2009-09-14 2011-03-17 The Regents Of The University Of Colorado Modulation of yeast-based immunotherapy products and responses
US20130121964A1 (en) 2010-03-14 2013-05-16 Globeimmune, Inc. Pharmacogenomic and Response-Guided Treatment of Infectious Disease Using Yeast-Based Immunotherapy
WO2012019127A2 (en) * 2010-08-05 2012-02-09 The Regents Of The University Of Colorado Combination yeast-based immunotherapy and arginine therapy for the treatment of myeloid-derived supressor cell-associated diseases
US9254320B2 (en) 2010-12-17 2016-02-09 Globeimmune, Inc. Compositions and methods for the treatment or prevention of human adenovirus-36 infection
MA34956B1 (en) 2011-02-12 2014-03-01 Globeimmune Inc THERAPY WITH YEAST FOR CHRONIC INFECTION WITH HEPATITIS B
CN103648513B (en) 2011-03-17 2018-10-12 全球免疫股份有限公司 Yeast-Brachyury (Brachyury) immunotherapeutic composition
BR112013032381B1 (en) 2011-06-14 2021-01-12 Globeimmune, Inc. yeast-based compositions and methods for treating or preventing infection by the hepatitis delta virus
CA2844500C (en) 2011-08-17 2022-05-10 Globeimmune, Inc. Yeast-muc1 immunotherapeutic compositions and uses thereof

Also Published As

Publication number Publication date
NZ616696A (en) 2015-09-25
RU2690180C2 (en) 2019-05-31
JP2018090634A (en) 2018-06-14
AU2012228937B2 (en) 2016-11-03
WO2012125998A1 (en) 2012-09-20
MX350661B (en) 2017-09-13
JP6309607B2 (en) 2018-04-11
EP3238731B1 (en) 2021-02-17
CA2835475C (en) 2020-06-30
HK1245649A1 (en) 2018-08-31
US20160106824A1 (en) 2016-04-21
PL2685995T3 (en) 2017-10-31
US20190374624A1 (en) 2019-12-12
JP2019199484A (en) 2019-11-21
EP2685995A1 (en) 2014-01-22
CN103648513A (en) 2014-03-19
US11938175B2 (en) 2024-03-26
DK2685995T3 (en) 2017-08-21
JP2014509595A (en) 2014-04-21
RU2619850C2 (en) 2017-05-18
US9198941B2 (en) 2015-12-01
RU2017116350A3 (en) 2018-10-17
EP2685995A4 (en) 2014-12-24
IL228421B (en) 2019-02-28
JP2017061570A (en) 2017-03-30
KR102046449B1 (en) 2019-11-19
SG193396A1 (en) 2013-10-30
RU2017116350A (en) 2018-10-17
JP6580733B2 (en) 2019-09-25
US20210106666A1 (en) 2021-04-15
CA2835475A1 (en) 2012-09-20
BR112013023456A2 (en) 2016-12-06
ES2627979T3 (en) 2017-08-01
US9623097B2 (en) 2017-04-18
JP6068368B2 (en) 2017-01-25
RU2013146324A (en) 2015-04-27
BR112013023456B1 (en) 2020-11-17
AU2018202972A1 (en) 2018-05-17
US20140004135A1 (en) 2014-01-02
AU2018202972B2 (en) 2019-08-29
EP3238731A1 (en) 2017-11-01
AU2017200715A1 (en) 2017-02-23
CN103648513B (en) 2018-10-12
US20170246276A1 (en) 2017-08-31
MX2013010475A (en) 2014-05-28
AU2012228937A1 (en) 2013-10-31
KR20140038387A (en) 2014-03-28
EP2685995B1 (en) 2017-05-03
IL228421A0 (en) 2013-12-31
US11944673B2 (en) 2024-04-02
PT2685995T (en) 2017-08-09
US10363294B2 (en) 2019-07-30
HUE033491T2 (en) 2017-12-28
AU2017200715B2 (en) 2018-05-31

Similar Documents

Publication Publication Date Title
HK1245649A1 (en) Yeast-brachyury immunotherapeutic compositions
IL257533B (en) Yeast-muc1 immunotherapeutic compositions and uses thereof
HK1203403A1 (en) Peracid-generating compositions
GB201117619D0 (en) Compositions
SG11201401335QA (en) Compositions
GB201117621D0 (en) Compositions
EP2763756A4 (en) Bromofluorocarbon compositions
GB2496447B (en) Compositions
GB201110833D0 (en) Compositions
GB201103942D0 (en) Compositions
HK1201687A1 (en) Improved compositions
GB201110132D0 (en) compositions
GB201104849D0 (en) Compositions
GB201114930D0 (en) Novel compositions
GB201108810D0 (en) Novel compositions
GB201122213D0 (en) Compositions
GB201122216D0 (en) Compositions
GB201122214D0 (en) Compositions
GB201121028D0 (en) Compositions
GB201120406D0 (en) Compositions
GB201117234D0 (en) Compositions
GB201117165D0 (en) Compositions
GB201114629D0 (en) Compositions
GB201109121D0 (en) Compositions
GB201108338D0 (en) Compositions